Related references
Note: Only part of the references are listed.Patterns of progression in patients treated for immuno-oncology antibodies combination
Alice Bernard-Tessier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G. Manson et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients
Kevin Prigent et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Classical Hodgkin lymphoma
Pauline Brice et al.
LANCET (2021)
Spleen Glucose Metabolism on [18F]-FDG PET/CT for Cancer Drug Dis-covery and Development cannot be Overlooked
Romain-David Seban et al.
CURRENT CANCER DRUG TARGETS (2021)
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT
Romain-David Seban et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature
Miruna Grecea et al.
ONCOLOGIST (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
Annie Wong et al.
CANCER IMAGING (2020)
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
Reid W. Merryman et al.
ONCOLOGIST (2020)
Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience
Joseph Liput et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2020)
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed of Refractory Hodgkin Lymphoma
Fatima-Zohra Mokrane et al.
RADIOLOGY (2020)
Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Hyo Jung Park et al.
RADIOLOGY (2020)
18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors
Angelo Castello et al.
LEUKEMIA & LYMPHOMA (2019)
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
Laurent Dercle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
Tomomi Nobashi et al.
CLINICAL NUCLEAR MEDICINE (2019)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunotherapy in Hodgkin Lymphoma: The Road Ahead
Stephen M. Ansell
TRENDS IN IMMUNOLOGY (2019)
PD-1 Tumor Suppressor Signaling in T Cell Lymphomas
Tim Wartewig et al.
TRENDS IN IMMUNOLOGY (2019)
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
Christos Sachpekidis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
Nicolas Aide et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
Alice Indini et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
Christos Sachpekidis et al.
MELANOMA RESEARCH (2019)
F-18-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor
Laurent Dercle et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
Guillaume Manson et al.
BLOOD (2018)
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
M. Tazdait et al.
EUROPEAN JOURNAL OF CANCER (2018)
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
Ahmed Mekki et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma
Joel C. Wight et al.
LEUKEMIA & LYMPHOMA (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
H. Bekoz et al.
ANNALS OF ONCOLOGY (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody
Jean-Marie Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes
Anita Kumar et al.
HAEMATOLOGICA (2016)
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes
Anita Kumar et al.
HAEMATOLOGICA (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-Staged Treatment-Naive Patients With Hodgkin Lymphoma
Tarec Christoffer El-Galaly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Abscopal Effect in a Patient with Melanoma
NEW ENGLAND JOURNAL OF MEDICINE (2012)
F-18-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Michal Weiler-Sagie et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
